Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild fro...
Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
About this item
Full title
Author / Creator
Publisher
New York: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
To explore the association of thrombo‐inflammatory biomarkers with severity in coronavirus disease (COVID‐19), we measured antiphospholipid antibodies (aPL) and calprotectin in sera of COVID‐19 patients.
Methods
Anticardiolipin antibodies (aCL) and anti‐β2‐glycoprotein I antibodies were measured using enzyme‐linked immunosorbent...
Alternative Titles
Full title
Assessment of antiphospholipid antibodies and calprotectin as biomarkers for discriminating mild from severe COVID‐19
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8605160
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8605160
Other Identifiers
ISSN
0887-8013
E-ISSN
1098-2825
DOI
10.1002/jcla.24004
